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The periodically hyperactive hypothalamic-pituitary-
adrenal (HPA) axis in bipolar affective disorders, as well
as the reported changes in the binding characteristics
of the glucocorticoid receptor (GR), suggest the poss-
ible involvement of the GR in the aetiopathology of this
disease. This was investigated by screening the coding
sequences of both GR isoforms, GRa and GRb, for the
presence of mutations. As a genetic predisposition has
been implicated, we included in this study bipolar
patients who were siblings. By RT-PCR of peripheral
blood mononuclear cells from patients suffering from
bipolar illness, using primers spanning the whole length
of the GRa and GRb coding region and subsequent aga-
rose gel electrophoresis, heteroduplex and sequence
analyses, no GR mutations could be detected. Since
glucocorticoid receptor activity can be modulated by
agents other than the respective ligand (eg by growth
factors, cytokines and stress signals), our results favor
derangements in the modulation of GR activity by such
agents and not in the primary structure of the receptor
as aetiopathologic factors of bipolar disease. Molecular
Psychiatry (2000) 5, 196–202.
Bipolar affective disorder and major depression are
considered stress-related diseases. A genetic predis-
position has been implicated; stressful life events,
however, are necessary to trigger the onset of these dis-
eases.1–3 An hyperactive hypothalamic-pituitary-adre-
nal (HPA) axis, serotonin depletion and a stimulation
of the sympathoadrenal system, reflecting central ner-
vous system stimulation, are consistent findings in
depression.4–6 Moreover, there is a loss of circadian
rhythm in the HPA axis function7 and a loss of sensi-
tivity to glucocorticoids, as shown by the lack of
response in the dexamethasone suppression test.8,9
Antidepressant therapy normalizes HPA axis activity
and catecholamine secretion, restores the regulatory
ability of glucocorticoids through the feedback mech-
anism,10,11 thus supporting signs and symptoms being
‘state dependent’ in this disease.
The glucocorticoid receptor (GR) has for long been
considered a primary factor in the aetiology of
depression. The hippocampus and hypothalamus are
rich in GR and are also the sites responsible for the
regulation of the circadian rhythm and the negative
feedback mechanism, therefore a defect in the number
and/or function of GR could be a causative factor for
disturbances seen in depression.12
Many studies concerning the binding characteristics
of GR (number of binding sites and affinity constant)
in human peripheral blood mononuclear cells of
depressed patients, compared to normal individuals,
reported results that are controversial and inconclus-
ive.13–17 However, no data on the molecular structure
of the GR in human bipolar illness have been reported.
The molecular structure of the GR and its gene have
been fully elucidated18–20 and important insights have
been obtained on the molecular mode of action of GR
by way of modulation of transcription and interaction
(cross-talk) with other key regulatory molecules.21–25
Mutations of GR at phosphorylation sites clustering
in the N-terminal transcriptional regulatory domain or
hormone binding domain have been reported to result
in enhanced or diminished sensitivity to glucocorti-
coids.26–28 Thus, mutations of the glucocorticoid recep-
tor, particularly on sites involved in the cross-talk of
GR with other regulatory systems (such as nervous
system), could alter GR activity and could explain the
‘state-dependent’ dysregulation of the HPA axis
activity present only during depressive episodes.
Moreover, a new isoform of the glucocorticoid recep-
tor, GRb, resulting from alternative splicing of the
hGRa pre-mRNA, has been described, which does not
bind glucocorticoids and by heterodimerization with
GRa exerts a dominant-negative effect on GRa action,
thus affecting tissue sensitivity to glucocorticoids.29 On
the basis of the above, we decided to investigate the
possible presence of mutations in the GRa and GRb
coding region in patients with bipolar illness by use of
RT-PCR, heteroduplex and sequence analyses.
We provide evidence that no such GR mutations
could be detected and maintain that defects in post-
translational modification of GR (such as
phosphorylation) evoked possibly by stress signals,
could alter GR activity and may be the aetiopathologic
factor of bipolar disease.
We have submitted to RT-PCR analysis and agarose
gel electrophoresis, RNA isolated from peripheral
blood mononuclear cells of 12 normal individuals and
15 patients suffering from bipolar affective disorder I
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or II, according to DSM-IV criteria. The patients were
under drug treatment in various phases of the illness
(Table 1). For comparison, we similarly analysed
samples from healthy individuals without a personal
or family history of psychiatric illness. We have used
six pairs of primers spanning the whole length of GRa,
plus one extra primer to cover the whole length of GRb.
The results shown in Figure 1 indicate that both full-
length wild-type GRa and GRb are expressed in PBMC
obtained from normal individuals and from patients.
Using the primer pair D, a lower mobility band
(LMB), in addition to the main band, was detected in
the preparations from both normal and depressed
patients, of still unknown structure. This PCR product,
containing both the main GR band and the LMB, was
submitted to RFLP analysis using the restriction
enzyme EcoRI which cleaves at 1628 bp of the GR gene
coding region. The restriction pattern was the one cor-
responding to GR, as the amplified product (364 bp)
was cleaved into two fragments of 276 bp and 88 bp,
as expected for GR. The LMB gave also an 88-bp frag-
ment and another fragment (LMBf) (results not shown)
of slightly lower mobility than the 276-bp fragment.
These results suggest that the lower mobility band is a
GR-variant whose detailed structure and biological role
remain to be elucidated.
All the PCR products were submitted to analysis for
the detection of mutations, using the heteroduplex
technique (Figure 2). The results depicted in Figure 2
reveal that no mutations can be detected in the prep-
arations either derived from normal or from bipolar
patients. The bands Ha and Hb (Figure 2D) correspond
to heteroduplexes formed between the wild-type GR
fragment and the LMB fragment which are present in
the PCR product using primer pair D.
An underlying concept of the study was that if GRa
gene alterations play a major role in the determination
Table 1 Demographic and clinical characteristics of the
patients
No. Name Gender Age Education Diagnosis Mood
(years) (years) state
1 TE F 69 6 BAD I D
2 AA F 44 12 BAD I D
3 AG M 70 12 BAD I N
4 AJ M 66 16 BAD II N
5 KM F 55 12 BAD I N
6 KA F 72 12 BAD I N
7 LV F 50 6 BAD II N
8 PV F 50 14 BAD I N
9 SA F 39 14 BAD I N
10 KD A 59 14 BAD I D
11 HI F 35 10 BAD I N
12 MA F 40 12 BAD I N
13 VE M 63 16 BAD I M
14 PM F 58 12 BAD I HM
15 KV F 49 16 BAD I D
BAD I or II: bipolar affective disorder I or II; D: depression;
N: normothymia; M: mania; HM: hypomania.
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of genetically linked bipolar patients, mutations or
polymorphisms should be shared more commonly than
expected by chance among these family pairs. There-
fore, sequence analysis was carried out in six patients
who were siblings. The results obtained documented
the absence of mutation or polymorphism of the GRa
gene.
In a recent study of an elderly population,30 five
polymorphisms in the glucocorticoid receptor gene
were identified, but they were not associated with gluc-
ocorticoid resistance, observed in this population, as
diagnosed by the use of an overnight dexamethasone
suppression test. Furthermore, a polymorphic variant
of GR, with a change of an Asparagine to Serine at
codon 363, has been reported.31 In the present work we
were unable to detect these polymorphisms, possibly
due to their low frequency (less than 5%).
The molecular action of glucocorticoids involves a
series of protein factors, such as heat shock proteins
(HSPs), transcription factors (AP-1, NFkB-Rel), histone
acetyl transferases and others.22 Shimizu et al32
described a 29-bp deletion in the 59 non coding region
and a 133-bp deletion in the coding sequence of HSP70
mRNA in depressed, but not in normal individuals. It
is worthwile to mention that altered patterns of the
transcription factor AP-1 have been reported in asthma
suggesting disturbed intracellular signalling and have
been linked to glucocorticoid sensitivity or resistance
observed in this disease.33 Therefore, the possibility
that transcription factors or genes for other proteins,
crucial for the expression of GR activity, may be affec-
ted in bipolar illness could be an important determi-
nant in the pathophysiology of depression.
As the relative levels of GRa to GRb (at the protein
or the mRNA level) could be a determinant of glucocor-
ticoid sensitivity, a quantitative study of GR or its
mRNA, applying Western Blot analysis or quantitative
PCR, respectively, warrants further investigation.
Phosphorylation of the GR represents a major post-
translational modification,34 induced by the steroid
ligand but also by cytokines, growth factors, stress sig-
nals and other regulatory molecules, by way of mul-
tiple kinases, which either positively or negatively
affect receptor evoked transcriptional enhancement,
indicating that a wide spectrum of regulatory inputs
could modulate, in conjunction with the steroid hor-
mones, the function of GR.24,25 Genetic defects in such
Figure 1 RT-PCR products of wild-type full length GR (GR)
from peripheral blood mononuclear cells of normal individ-
uals (1–5) and of patients with bipolar affective disorder (6–
10). Total RNA was obtained and amplified using specific pri-
mers. Primer pairs A–F were used to amplify fragments of
hGRa cDNA, whereas primer pair G was used to amplify a
fragment specific to the hGRb cDNA sequence. PCR products
were submitted to electrophoresis in 3% agarose gel and vis-
ualized after staining with ethidium bromide. Arrows point
to the expected size of PCR products (GR) as well as to the
lower mobility band (LMB). Results shown are representative
of 12 different normal individuals and 15 patients.
M = marker, B = blank, W = GRa cDNA.
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Figure 2 Heteroduplex analysis. Total RNA was obtained from normal individuals (1–5) and patients affected by bipolar
illness (6–10) and amplified using specific primers (A–G). PCR products were submitted to heteroduplex analysis using MDE
polyacrylamide gels and GR cDNA fragments were visualized after silver staining. Arrows point to the expected GR homoduplex
molecules. C = commercial control sample containing a mixture of homoduplex (b) and heteroduplex molecules (a). C9 = In
house control sample of known mutation submitted to heteroduplex analysis. A mixture of homoduplex molecules (x) and
heteroduplex molecules (y, z) were obtained. Heteroduplex analysis of Ha, Hb = GR cDNA fragment and lower mobility band
(LMB) obtained after PCR-amplification using primer pair D, gave heteroduplex molecules Ha and Hb.
enzymatic proteins, involved in signal transduction,
crucial for the receptor’s function, could be a key factor
in the pathophysiology of bipolar illness and a future
research target in the study of depression.
Moreover, an imbalance between neural signals
(known to be altered in depressed patients) and
corticosteroids, both modulating glucocorticoid recep-
tor transcriptional activity by way of posttranslational
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modification, could be a causative factor altering GR
function during depressive episodes. Such a concept
could possibly explain the ‘transient state’ of hypercor-
tisolaemia and the loss of sensitivity to glucocorticoids
observed in the depressive phase. The use of serotonin
reuptake inhibitors as antidepressant therapy restoring
HPA axis dysregulation, as well as reports from an earl-
ier work35 in which increased serotonin availability
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augmented cortisol-induced feedback inhibition in
humans, is supportive of this concept.
Methods
Patient data
Fifteen patients (four males and 11 females) suffering
from bipolar I or II affective disorders, according to
DSM-IV criteria for mental illnesses, and 12 normal
control subjects (six males and six females), sharing the
same sociodemographic characteristics, participated in
this study. All patients attended the Outpatients’ Clinic
of Athens University Department of Psychiatry,
whereas the controls were laboratory personnel
(Athens University, Biological Chemistry Department),
with no personal or family psychiatric history. The age
range of patients was 39–72 years and that of controls
24–45 years. Table 1 shows the main demographic and
clinical characteristics of the patients. Among the 15
patients, three couples were siblings (Nos. 3 and 4, 5
and 6, 13 and 14). All patients were under drug treat-
ment, such as lithium or carbamazepine and phenothi-
azines. The patients’ mood state was normothymic
(nine patients), depressed (four patients) and manic
(two patients). All subjects gave their consent that the
material be used for research purposes.
Sample collection
Venous blood (20 ml) was collected into precooled
heparinized vacutainers, placed immediately on ice
and peripheral blood mononuclear cells were isolated
by Ficoll Hypaque gradient centrifugation. The number
of cells as well as their viability was determined. Cellu-
Figure 3 Schematic representation of human GR cDNA consisting of 10 exons (open boxes). Human GRa cDNA contains exon
9a (in addition to the first eight exons) and human GRb cDNA contains exon 9b. Exon 1 is a non coding sequence, exon 2
encodes for the N-terminal domain of the GR protein molecule, exon 3 and exon 4 for the DNA-binding domain, and exon 5–
exon 9a for the hormone-binding domain. The two isoforms have the first 727 NH2-terminal aminoacids in common, so they
both contain the transactivation and the DNA-binding domains. hGRb contains in its COOH-terminus a unique 15-aminoacid
sequence in place of the last 50 aminoacids of the hGRa isoform, does not bind glucocorticoid hormones and is transcrip-
tionally inactive.
lar RNA was isolated from PBMC according to a direct
RNA extraction protocol (QIAGEN ‘Rneasy Protocol for
isolation of total RNA from Tissues and Eukaryotic
Cells’). The concentration, total yield and purity of
RNA was determined spectrophotometrically by meas-
uring absorbance at 260 nm and 280 nm (ratio A260:
A280 = 1.8–2.0).
Reverse transcription-PCR amplification
Total RNA (0.5 mg per reaction) denatured at 70 ° C for
3 min, RNasin (20 IU per reaction, Promega, Madison,
WI, USA) was added and subsequently reverse tran-
scribed in a final volume of 20 ml made with the reac-
tion buffer supplied with the M-MLV reverse tran-
scriptase (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM
MgCl2, 10 mM DTT final concentrations) in the pres-
ence of M-MLV reverse transcriptase (200 units per
reaction, Moloney Murine Leukemia Virus Reverse
Transcriptase, Promega), random hexamers (0.5 mg per
reaction, Promega) and dNTPs (final concentration
1 mM each). The reaction was allowed to proceed for
60 min at 37 ° C, terminated by heating at 95 ° C for 5 min
and the preparation placed immediately on ice.
The total reaction mixture (20 ml) was submitted to
PCR amplification by using seven pairs of primers, spe-
cific to the human glucocorticoid receptor gene coding
region (hGRa cDNA and hGRb cDNA) (Figure 3), which
are the following: Primer pair A (map position
125–573, 59ATTCACTGATGGACTCCAAAGAATCA-39,
59-CACAGCAGTGGATGCTGAACTCTTGG-39); primer
pair B (map position 547–954, 59-CCAAGAGTTCA
GCATCCACTGCTGTG-39, 59-ACTTGGGGCAGTGTTA
CATTACT-39); primer pair C (map position 936–1376,
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59-CAGTAATGTAACACTGCCCCAAGT-39, 59-CCTG
TTGTTGCTGTTGAGGAGCTGG-39); primer pair D
(map position 1352–1716, 59-CCAGCTCCTCAACA
GCAACAACAGG-39, 59-GAGTTGTGGTAACGTTGC
AGGAC-39); primer pair E (map position 1693–2070,
59-GTTCCTGCAACGTTACCACAACTC-39, 59-CATG
TGTTTACATTGGTCGTACATGC-39); primer pair F
(map position 2045–2471, 59-GCATGTACGACCAAT
GTAAAC ACATG-39, 59-GGCAGTCACTTTTGATGAA
ACAGAAG-39); primer pair G (map position 2045–2358,
59-GCATGTACGACCAATGTAAACACATG-39, 59-GAT
TAATGTGTGAGATGTGCTTTCTG-39) (numbering of
nucleotides according to Hollenberg et al18). The PCR
reaction volume (100 ml) contained 10 mM Tris-HCl
pH 9.0, 50 mM KCl, 1.5 mM MgCl2, dNTPs (final
concentration/200 mM each), 1 ml of each primer
(4 ng ml - 1) and 0.3 IU Taq polymerase (Promega). The
PCR conditions were: 35 cycles of 2 min at 94° C
(denaturation), 1.5 min at 63° C (annealing), 1 min at
72° C (extension), followed by one cycle at 72° C for
10 min and then stored at 4° C.
In each PCR experiment a tube without template was
included, to check for contamination by extraneous
genomic DNA or cDNA. Another tube containing plas-
mid GRa cDNA or GRb cDNA was also included in
each amplification experiment to control PCR speci-
ficity conditions. Each pair of primers used was com-
pared to GeneBank sequence libraries to assure specific
amplification of human GR cDNA. PCR products
(10 ml) were submitted to electrophoresis on a 3% aga-
rose gel. After staining with ethidium bromide they
were evaluated by comparison to reference size mark-
ers FX174 DNA, HaeIII (Promega) and to 100-bp DNA
ladder (Gibco BRL, Gaithersburg, MD, USA). Restric-
tion fragment length polymorphism (RFLP) using the
enzyme EcoRI (Promega) was carried out to elucidate
the nature of a faint band with slightly lower mobility
(LMB) than the wild-type GR band obtained by using
the primer pair D.
EcoRI digestion was carried out in a total volume of
50 ml: PCR products (15 ml) were mixed with the
appropriate buffer (5 ml) (2.5 mM pH 7.8, 10 mM pot-
assium acetate, 1 mM magnesium acetate, 0.1 mM DTT
final concentration, Promega) in the presence of bovine
serum albumin (0.5 ml, final concentration 100 ng ml - 1),
H2O (27.5 ml) and EcoRI (20–24 IU).
Heteroduplex analysis
The PCR product from patient samples (2 ml) was
mixed with an equal volume of the PCR product from
a normal sample heated for 4 min at 95° C, sub-
sequently left to attain room temperature and then sub-
jected to heteroduplex analysis using MDE (mutation
detection enhancement) polyacrylamide gels (FMC)
(1 · MDE, 0.6 · TBE, 0.6 · APS (10%), 0.06 · TEMED
final concentration). The samples (4 ml) were submitted
to electrophoresis for 20 h at 650 V and cDNA frag-
ments were visualized after silver staining. In each het-
eroduplex analysis experiment a tube containing a
known heteroduplex mixture (heteroduplex control,
Promega) as well as an in-house control sample were
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included to serve as control and to assure proper heter-
oduplex analysis.
Sequence analysis of PCR products
The PCR products spanning the whole length of GRa
from six patients (three couples who were siblings; 3
and 4, 5 and 6, 13 and 14, Table 1) were sequenced as
follows. The purified (by use of Qiaquick spin kit,
Qiagen) PCR products (500 ng) were amplified in a
sequencing reaction volume (20 ml) containing the
appropriate labelled primers, buffer and Taq poly-
merase. Amplification was performed on Perkin Elmer
9600 (95° C for 2 min, and 95 ° C for 30 s, 52° C for 25
cycles). Stop solution was added and denaturation
(92° C for 2 min) followed before loading on a denatur-
ating sequencing gel (42% w/v urea, 0.6 · TBE and 6%
Long Ranger gel solution FMC). The gel was run on
ALF express Pharmacia Automated Sequencer for
800 min at 1500 V at 55° C.
The sequencing procedure as described above was
carried out in Microchemistry Lab, Foundation for
Research and Technology Hellas (FORTH, Greece), PO
Box 1527, Herakleion 71110 Crete, Greece.
Accession number
The numbering of nucleotides for the GRa and GRb
gene coding region was based on accession numbers
M10901 and M11050, respectively.
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